Categories
Uncategorized

Nateglinide

A short-acting insulin secretogue.

Assignment of this agent for 5 years did not reduce the incidence of diabetes or cardiovascular outcomes among persons with impaired glucose tolerance with established cardiovascular disease or cardiovascular risk factors (NAVIGATOR Study Group).

Leave a Reply

Your email address will not be published. Required fields are marked *